Ethinylestradiol belongs to the class of compounds known as estrogens, which play a crucial role in the regulation of the female reproductive system.
It functions by binding to estrogen receptors in target tissues, thereby modulating gene expression and affecting various physiological processes.
Ethinylestradiol has a higher oral bioavailability and is more resistant to metabolism compared to natural estradiol, making it suitable for use in oral contraceptive formulations.
While ethinylestradiol can offer significant benefits, it is important to consider potential side effects and risks:
Thromboembolic Events: Use of ethinylestradiol-containing contraceptives is associated with a slightly increased risk of venous thromboembolism (VTE) and arterial thrombotic events.
Cardiovascular Risks: Combined oral contraceptives with ethinylestradiol may pose a small increase in the risk of cardiovascular events, particularly in women with preexisting risk factors.
Breast Cancer: Long-term use of estrogen-containing medications like ethinylestradiol may be associated with a slightly increased risk of breast cancer.
Hormonal Fluctuations: Discontinuation of ethinylestradiol-containing contraceptives can lead to hormone-related symptoms, including irregular bleeding and mood changes.
Drug Interactions: Ethinylestradiol may interact with certain medications, affecting their efficacy or increasing the risk of side effects.
While it offers benefits in regulating the female reproductive system and managing menopausal symptoms, potential side effects and risks must be carefully considered.
Individualized patient assessment and ongoing communication between healthcare providers and patients are essential for ensuring safe and effective use of ethinylestradiol and optimizing women's health.
Sitruk-Ware, R., & Nath, A. (2010). Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Practice & Research Clinical Endocrinology & Metabolism, 24(4), 553-571.
Wiegratz, I., Kuhl, H., & Lee, J. H. (2017). Clinical Efficacy and Safety of Ethinylestradiol 20 μg/drospirenone 3 mg in a Continuous/Extended‐Cycle Regimen in Comparison to the 21/7 Cycle. The Journal of Sexual Medicine, 14(5), 726-738.
Lobo, R. A., Davis, S. R., & De Villiers, T. J. (2014). Prevention of diseases after menopause. Climacteric, 17(5), 540-556.